Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration

Journal of Rheumatology

Volumn 35, Issue 9, 2008, Pages 1896-1897

  Toki, Hiroe ^a   Momohara, Shigeki ^a   Tsukahara, So ^a   Ikari, Katsunori ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; ETANERCEPT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

AGED; ANTIBODY PRODUCTION; CASE REPORT; DISEASE ACTIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; HUMAN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LETTER; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT RESPONSE; URTICARIA;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54049155798     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Baraliakos X, Listing J, Rudwaleit M, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007;34:510-5.
2. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:667-77.
3. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
5. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1462-6.
6. Uthman I, Touma Z, El-Sayyad J, Zaitoun F. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 2006;25:540-1.
7. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
8. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
9. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
10. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.